For many investors, the main point of stock picking is to generate higher returns than the overall market. But if ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

SCHD ETF effectively combines dividend income and dividend growth, while offering investors a reduced Expense Ratio. Click ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ongoing BEACON Phase 1/2 ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...